Literature DB >> 31240636

Transparency in Decision Modelling: What, Why, Who and How?

Christopher James Sampson1, Renée Arnold2, Stirling Bryan3, Philip Clarke4, Sean Ekins5, Anthony Hatswell6, Neil Hawkins7, Sue Langham8, Deborah Marshall9, Mohsen Sadatsafavi10, Will Sullivan11, Edward C F Wilson12, Tim Wrightson13.   

Abstract

Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the 'what', 'why', 'who' and 'how'. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.

Entities:  

Mesh:

Year:  2019        PMID: 31240636      PMCID: PMC8237575          DOI: 10.1007/s40273-019-00819-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  46 in total

1.  Being economical with the truth: how to make your idea appear cost effective.

Authors:  S Goodacre; C McCabe
Journal:  Emerg Med J       Date:  2002-07       Impact factor: 2.740

2.  Publication bias in clinical trials and economic analyses.

Authors:  N Freemantle; J Mason
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

3.  Publication bias in health economic studies.

Authors:  J A Sacristán; E Bolaños; J M Hernández; J Soto; I Galende
Journal:  Pharmacoeconomics       Date:  1997-03       Impact factor: 4.981

4.  The HTA core model: a novel method for producing and reporting health technology assessments.

Authors:  Kristian Lampe; Marjukka Mäkelä; Marcial Velasco Garrido; Heidi Anttila; Ilona Autti-Rämö; Nicholas J Hicks; Björn Hofmann; Juha Koivisto; Regina Kunz; Pia Kärki; Antti Malmivaara; Kersti Meiesaar; Päivi Reiman-Möttönen; Inger Norderhaug; Iris Pasternack; Alberto Ruano-Ravina; Pirjo Räsänen; Ulla Saalasti-Koskinen; Samuli I Saarni; Laura Walin; Finn Børlum Kristensen
Journal:  Int J Technol Assess Health Care       Date:  2009-12       Impact factor: 2.188

5.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Authors:  Gerardus W J Frederix; Hossein Haji Ali Afzali; Erik J Dasbach; Robyn L Ward
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

6.  Advantages of a Truly Open-Access Data-Sharing Model.

Authors:  Monica M Bertagnolli; Oliver Sartor; Bruce A Chabner; Mace L Rothenberg; Sean Khozin; Charles Hugh-Jones; David M Reese; Martin J Murphy
Journal:  N Engl J Med       Date:  2017-03-23       Impact factor: 91.245

7.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 8.  Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake.

Authors:  Gregory Merlo; Katie Page; Julie Ratcliffe; Kate Halton; Nicholas Graves
Journal:  Appl Health Econ Health Policy       Date:  2015-06       Impact factor: 2.561

9.  UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

Authors:  A J Hayes; J Leal; A M Gray; R R Holman; P M Clarke
Journal:  Diabetologia       Date:  2013-06-22       Impact factor: 10.122

10.  The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.

Authors:  George A K van Voorn; Pepijn Vemer; Dominique Hamerlijnck; Isaac Corro Ramos; Geertruida J Teunissen; Maiwenn Al; Talitha L Feenstra
Journal:  Appl Health Econ Health Policy       Date:  2016-04       Impact factor: 2.561

View more
  10 in total

1.  Improving Transparency in Decision Models: Current Issues and Potential Solutions.

Authors:  Paul Tappenden; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

2.  Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.

Authors:  Deborah A Marshall; Luiza R Grazziotin; Dean A Regier; Sarah Wordsworth; James Buchanan; Kathryn Phillips; Maarten Ijzerman
Journal:  Value Health       Date:  2020-03-26       Impact factor: 5.725

3.  Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time.

Authors:  Gemma E Shields; Becky Pennington; Ash Bullement; Stuart Wright; Jamie Elvidge
Journal:  Pharmacoeconomics       Date:  2021-12-06       Impact factor: 4.981

4.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

5.  Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.

Authors:  Stephanie Harvard; Amin Adibi; Adam Easterbrook; Gregory R Werker; David Murphy; Don Grant; Alison Mclean; Zhina Majdzadeh; Mohsen Sadatsafavi
Journal:  Pharmacoeconomics       Date:  2022-07-30       Impact factor: 4.558

6.  Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India.

Authors:  Yashika Chugh; Pankaj Bahuguna; Aamir Sohail; Kavitha Rajsekar; V R Muraleedharan; Shankar Prinja
Journal:  Appl Health Econ Health Policy       Date:  2022-10-19       Impact factor: 3.686

7.  A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.

Authors:  Fernando Alarid-Escudero; Eline M Krijkamp; Petros Pechlivanoglou; Hawre Jalal; Szu-Yu Zoe Kao; Alan Yang; Eva A Enns
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

8.  Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest.

Authors:  Stephanie Harvard; Gregory R Werker
Journal:  Pharmacoeconomics       Date:  2021-05-07       Impact factor: 4.981

9.  Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.

Authors:  Josh J Carlson; Surrey M Walton; Anirban Basu; Richard H Chapman; Jonathan D Campbell; R Brett McQueen; Steven D Pearson; Daniel R Touchette; David Veenstra; Melanie D Whittington; Daniel A Ollendorf
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 10.  A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Authors:  Wei Gao; Dominic Muston; Matthew Monberg; Kimmie McLaurin; Robert Hettle; Elizabeth Szamreta; Elyse Swallow; Su Zhang; Iden Kalemaj; James Signorovitch; R Brett McQueen
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.